January started the year off strong, with several business updates, long-term clinical trial results on multiple biosimilars, ...

which is FDA-approved for plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis – as well as Johnson & Johnson's Stelara (ustekinumab) and Tremfya (guselkumab), Eli ...

If it reaches the market, JNJ-2113 could extend J&J's psoriasis franchise, currently represented by injectable IL-12 and IL-23 inhibitor Stelara (ustekinumab) – which made $2.75 billion in sales ...

B Health and two safety-net hospitals want to help the government prove that drugmakers are required to give upfront ...

Alvotech (NASDAQ:ALVO – Get Free Report) shares gapped up prior to trading on Friday . The stock had previously closed at $12.41, but opened at $12.80. Alvotech shares last traded at $12.87, with a ...

AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030. Learn more on ABBV stock here.

Jan. 31, 2025 — In a new study, researchers have determined that a protein called NF-kB c-Rel can intensify the symptoms of psoriasis when activated by signals from the body's immune system.

Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast ...

After hours: February 3 at 4:01:47 PM EST Loading Chart for ALVO ...